GlaxoSmithKline PLC (NYSE:GSK) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b” rating in a research note issued on Wednesday.

Other analysts also recently issued reports about the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Tuesday. Bank of America Corporation cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $44.33.

GlaxoSmithKline PLC (GSK) traded down 1.01% on Wednesday, hitting $36.23. 6,898,215 shares of the stock traded hands. The company’s 50 day moving average price is $40.27 and its 200-day moving average price is $41.42. The stock has a market capitalization of $88.55 billion, a P/E ratio of 35.11 and a beta of 1.03. GlaxoSmithKline PLC has a 12-month low of $36.16 and a 12-month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 7.79% and a return on equity of 115.30%. Analysts predict that GlaxoSmithKline PLC will post $2.89 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Raised to “B” at TheStreet” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/28/glaxosmithkline-plc-gsk-raised-to-b-at-thestreet.html.

Several institutional investors and hedge funds have recently modified their holdings of GSK. Russell Investments Group Ltd. bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth approximately $578,000. CWA Asset Management Group LLC grew its stake in shares of GlaxoSmithKline PLC by 13.5% during the 1st quarter. CWA Asset Management Group LLC now owns 6,320 shares of the pharmaceutical company’s stock worth $266,000 after acquiring an additional 750 shares in the last quarter. Banque Pictet & Cie SA bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth approximately $208,000. Thrivent Financial For Lutherans grew its stake in shares of GlaxoSmithKline PLC by 87,023.5% during the 1st quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after acquiring an additional 1,371,490 shares in the last quarter. Finally, Balentine LLC grew its stake in shares of GlaxoSmithKline PLC by 11.6% during the 1st quarter. Balentine LLC now owns 5,439 shares of the pharmaceutical company’s stock worth $229,000 after acquiring an additional 566 shares in the last quarter. 9.31% of the stock is owned by institutional investors.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.